Atai Beckley N.V.(ATAI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,653 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
ATAI Stock Analysis & AI Quality Score
Data updated 2026-08-29AI stock analysis and institutional research for Atai Beckley N.V. (ATAI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ATAI at 25.6/100 on a 32-signal composite quality model, placing it at rank #2,653 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Atai Beckley N.V. reports quarterly revenue of $1.7M, net income of $-32.5M, free cash flow of $-35.3M. Top institutional holders of ATAI by reported 13-F value include BlackRock, Deep Track Capital, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ATAI trades on the Nasdaq exchange and files with the SEC under CIK 1840904. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATAI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Atai Beckley N.V. directly from SEC EDGAR.
Revenue
Q2 2026
$1.7M
Net Income
Q2 2026
$-32.5M
Free Cash Flow
Q2 2026
$-35.3M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+1227.6% YoYNet Income
-342.2% YoYOperating Income
-527.2% YoYEPS (Diluted)
-212.9% YoYTotal Assets
+83.7% YoYTotal Debt
+107.3% YoYOp. Cash Flow
-24.5% YoYFree Cash Flow
-25.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $4.1M +1227.6% | $308.0K -1.9% | $314.0K +34.8% | $233.0K -98.9% | $20.4M | $0.00 |
| Net Income | $-660.0M -342.2% | $-149.3M -271.1% | $-40.2M +73.6% | $-152.4M +9.2% | $-167.8M +1.2% | $-169.8M |
| Operating Income | $-644.1M -527.2% | $-102.7M +18.2% | $-125.5M +13.3% | $-144.8M -6.6% | $-135.8M -30.4% | $-104.2M |
| EPS (Diluted) | $-2.91 -212.9% | $-0.93 -272.0% | $-0.25 +74.5% | $-0.98 +19.0% | $-1.21 | — |
| Total Assets | $292.7M +83.7% | $159.4M -45.7% | $293.5M -3.9% | $305.4M -26.3% | $414.2M +271.3% | $111.5M |
| Total Debt | $135.4M +107.3% | $65.3M -47.4% | $124.2M +27.8% | $97.2M | $0.00 | — |
| Operating Cash Flow | $-102.7M -24.5% | $-82.4M +2.0% | $-84.1M +19.5% | $-104.5M -65.2% | $-63.2M -204.6% | $-20.8M |
| Free Cash Flow | $-103.6M -25.6% | $-82.4M +2.3% | $-84.4M +19.8% | $-105.2M -65.9% | $-63.4M -204.5% | $-20.8M |
Get alerted when ATAI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Atai Beckley N.V. including:
Top Institutional Holders of ATAI
BlackRock, Inc.
$134.8M25,574,573 shDeep Track Capital, LP
$76.0M14,417,442 shVANGUARD CAPITAL MANAGEMENT LLC
$61.9M11,747,249 shSTATE STREET CORP
$43.7M8,287,054 shGEODE CAPITAL MANAGEMENT, LLC
$36.5M6,933,309 shADAGE CAPITAL PARTNERS GP, L.L.C.
$29.7M5,642,758 shUBS Group AG
$23.3M4,424,701 shVANGUARD PORTFOLIO MANAGEMENT LLC
$21.6M4,106,450 shMORGAN STANLEY
$20.3M3,843,253 shCandriam S.C.A.
$16.0M3,039,399 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $134.8M | 25,574,573 |
| Deep Track Capital, LP | $76.0M | 14,417,442 |
| VANGUARD CAPITAL MANAGEMENT LLC | $61.9M | 11,747,249 |
| STATE STREET CORP | $43.7M | 8,287,054 |
| GEODE CAPITAL MANAGEMENT, LLC | $36.5M | 6,933,309 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $29.7M | 5,642,758 |
| UBS Group AG | $23.3M | 4,424,701 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $21.6M | 4,106,450 |
| MORGAN STANLEY | $20.3M | 3,843,253 |
| Candriam S.C.A. | $16.0M | 3,039,399 |
Companies Similar to ATAI
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
PROKIDNEY CORP.
CG Oncology, Inc.
Upstream Bio, Inc.
4D Molecular Therapeutics, Inc.
Orchestra BioMed Holdings, Inc.
TScan Therapeutics, Inc.
Prime Medicine, Inc.
Inhibrx Biosciences, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ATAI on your watchlist
Track score changes the day Atai Beckley N.V. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ATAI a good stock to buy?
13F Pro's AI-powered analysis of Atai Beckley N.V. (ATAI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ATAI are available on the ATAI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ATAI is classified as a mid company.
Which hedge funds own ATAI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ATAI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Atai Beckley N.V.'s investment landscape.